Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease

被引：0
作者：
Wen-sheng Yang
Jing-lin Wang
Wei Wu
Guang-fei Wang
Jun Yan
Qing Liu
Xiao-yan Wu
Qing-tong Zhou
De-hua Yang
Ming-Wei Wang
Zhi-ping Li
机构：
[1] National Children’s Medical Center,Department of Pharmacy, Children’s Hospital of Fudan University
[2] Huazhong University of Science and Technology,Department of Pharmacy, Union Hospital, Tongji Medical College
[3] Fudan University,Department of Laboratory Animal Science
[4] Chinese Academy of Sciences,The National Center for Drug Screening, Shanghai Institute of Materia Medica
[5] Research Center for Deepsea Bioresources,Department of Pharmacology, School of Basic Medical Sciences
[6] Fudan University,undefined
来源：
Acta Pharmacologica Sinica | 2023年 / 44卷
关键词：
resolution; inflammation; FPR2/ALX; SPM; IBD; pro-resolving;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Inflammatory bowel disease (IBD) is a global health burden whose existing treatment is largely dependent on anti-inflammatory agents. Despite showing some therapeutic actions, their clinical efficacy and adverse events are unacceptable. Resolution as an active and orchestrated phase of inflammation involves improper inflammatory response with three key triggers, specialized pro-resolving mediators (SPMs), neutrophils and phagocyte efferocytosis. The formyl peptide receptor 2 (FPR2/ALX) is a human G protein-coupled receptor capable of binding SPMs and participates in the resolution process. This receptor has been implicated in several inflammatory diseases and its association with mouse model of IBD was established in some resolution-related studies. Here, we give an overview of three reported FPR2/ALX agonists highlighting their respective roles in pro-resolving strategies.
引用
收藏
页码：19 / 31
页数：12
相关论文
共 805 条
  • [1] Chang JT(2020)Pathophysiology of inflammatory bowel diseases N Engl J Med 383 2652-64.
  • [2] Kaplan GG(2021)The four epidemiological stages in the global evolution of inflammatory bowel disease Nat Rev Gastroenterol Hepatol 18 56-66
  • [3] Windsor JW(2015)The global burden of IBD: From 2015 to 2025 Nat Rev Gastroenterol Hepatol 12 720-7
  • [4] Kaplan GG(2013)The history of 5-ASA compounds and their use in ulcerative colitis-trailblazing discoveries in gastroenterology J Gastrointestin Liver Dis 22 375-7
  • [5] Mayberry J(2017)Emerging biologics in inflammatory bowel disease J Gastroenterol 52 141-50.
  • [6] Chan HC(2020)Resolution of inflammation and gut repair in IBD: Translational steps towards complete mucosal healing Inflamm Bowel Dis 26 1131-43.
  • [7] Ng SC(2015)Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases Ther Adv Gastroenterol 8 66-82
  • [8] Ho GT(2017)Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial Lancet 390 2779-89.
  • [9] Cartwright JA(2022)Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from china with inflammatory bowel disease: Results from the explore study BMC Gastroenterol 22 44-30.
  • [10] Thompson EJ(2017)Resolution of inflammation in inflammatory bowel disease Lancet Gastroenterol Hepatol 2 521-73.
12345678910